474 related articles for article (PubMed ID: 33067414)
1. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM).
Mateos MV; Kumar S; Dimopoulos MA; González-Calle V; Kastritis E; Hajek R; De Larrea CF; Morgan GJ; Merlini G; Goldschmidt H; Geraldes C; Gozzetti A; Kyriakou C; Garderet L; Hansson M; Zamagni E; Fantl D; Leleu X; Kim BS; Esteves G; Ludwig H; Usmani S; Min CK; Qi M; Ukropec J; Weiss BM; Rajkumar SV; Durie BGM; San-Miguel J
Blood Cancer J; 2020 Oct; 10(10):102. PubMed ID: 33067414
[TBL] [Abstract][Full Text] [Related]
2. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma.
Dispenzieri A; Kyle RA; Katzmann JA; Therneau TM; Larson D; Benson J; Clark RJ; Melton LJ; Gertz MA; Kumar SK; Fonseca R; Jelinek DF; Rajkumar SV
Blood; 2008 Jan; 111(2):785-9. PubMed ID: 17942755
[TBL] [Abstract][Full Text] [Related]
3. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria.
Lakshman A; Rajkumar SV; Buadi FK; Binder M; Gertz MA; Lacy MQ; Dispenzieri A; Dingli D; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Kapoor P; Leung N; Go RS; Lin Y; Kourelis TV; Warsame R; Lust JA; Russell SJ; Zeldenrust SR; Kyle RA; Kumar SK
Blood Cancer J; 2018 Jun; 8(6):59. PubMed ID: 29895887
[TBL] [Abstract][Full Text] [Related]
4. The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective.
Caers J; Fernández de Larrea C; Leleu X; Heusschen R; Zojer N; Decaux O; Kastritis E; Minnema M; Jurczyszyn A; Beguin Y; Wäsch R; Palumbo A; Dimopoulos M; Mateos MV; Ludwig H; Engelhardt M
Oncologist; 2016 Mar; 21(3):333-42. PubMed ID: 26921288
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of involved/uninvolved free light chain ratio determined by Freelite and N Latex FLC assays for identification of high-risk smoldering myeloma patients.
Henriot B; Rouger E; Rousseau C; Escoffre M; Sébillot M; Bendavid C; Minvielle S; Avet-Loiseau H; Decaux O; Moreau C
Clin Chem Lab Med; 2019 Aug; 57(9):1397-1405. PubMed ID: 30973821
[TBL] [Abstract][Full Text] [Related]
7. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma.
Larsen JT; Kumar SK; Dispenzieri A; Kyle RA; Katzmann JA; Rajkumar SV
Leukemia; 2013 Apr; 27(4):941-6. PubMed ID: 23183428
[TBL] [Abstract][Full Text] [Related]
8. Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study.
Sørrig R; Klausen TW; Salomo M; Vangsted AJ; Østergaard B; Gregersen H; Frølund UC; Andersen NF; Helleberg C; Andersen KT; Pedersen RS; Pedersen P; Abildgaard N; Gimsing P;
Eur J Haematol; 2016 Sep; 97(3):303-9. PubMed ID: 26710662
[TBL] [Abstract][Full Text] [Related]
9. Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling.
Wu V; Moshier E; Leng S; Barlogie B; Cho HJ; Jagannath S; Madduri D; Mazumdar M; Parekh S; Chari A
Blood Adv; 2018 Jun; 2(12):1470-1479. PubMed ID: 29945937
[TBL] [Abstract][Full Text] [Related]
10. Baseline serum B-cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma.
Bujarski S; Goldwater MS; Regidor BS; Jew S; Daniely D; Swift RA; Eades BM; Emamy-Sadr M; Souther E; Li M; Wang C; Xu N; Chen H; Spektor TM; Berenson JR
Eur J Haematol; 2021 Sep; 107(3):318-323. PubMed ID: 33993536
[TBL] [Abstract][Full Text] [Related]
11. [Analysis of serum free light chains κ/λ ratio and heavy/light chain pairs of immunoglobulin to the stratification of multiple myeloma according to Mayo Stratification of Myeloma and Revised International Staging System].
Ščudla V; Balcárková J; Lochman P; Vincová M; Pika T; Minařík J; Zapletalová J; Jarošová M
Vnitr Lek; 2016 Apr; 62(4):269-80. PubMed ID: 27250604
[TBL] [Abstract][Full Text] [Related]
12. Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma.
Termini R; Žihala D; Terpos E; Perez-Montaña A; Jelínek T; Raab M; Weinhold N; Mai EK; Grab AL; Corre J; Vergez F; Sacco A; Chiarini M; Giustini V; Tucci A; Rodriguez S; Moreno C; Perez C; Maia C; Martín-Sánchez E; Guerrero C; Botta C; Garces JJ; Lopez A; Tamariz-Amador LE; Prosper F; Bargay J; Cabezudo ME; Ocio EM; Hájek R; Martinez-Lopez J; Solano F; Iglesias R; Paiva A; Geraldes C; Vitoria H; Gomez C; De Arriba F; Ludwig H; Garcia-Guiñon A; Casanova M; Alegre A; Cabañas V; Sirvent M; Oriol A; de la Rubia J; Hernández-Rivas JÁ; Palomera L; Sarasa M; Rios P; Puig N; Mateos MV; Flores-Montero J; Orfao A; Goldschmidt H; Avet-Loiseau H; Roccaro AM; San-Miguel JF; Paiva B;
Clin Cancer Res; 2022 Nov; 28(21):4771-4781. PubMed ID: 36074126
[TBL] [Abstract][Full Text] [Related]
13. [Significant changes in diagnostic and therapeutic procedures in smoldering multiple myeloma].
Jurczyszyn A; Olszewska-Szopa M; Skotnicki AB
Przegl Lek; 2015; 72(11):642-8. PubMed ID: 27012123
[TBL] [Abstract][Full Text] [Related]
14. Testing Mayo Clinic's New 20/20/20 Risk Model in Another Cohort of Smoldering Myeloma Patients: A Retrospective Study.
Tessier C; Allard T; Boudreault JS; Kaedbey R; Éthier V; Fortin F; Pavic M
Curr Oncol; 2021 May; 28(3):2029-2039. PubMed ID: 34073289
[TBL] [Abstract][Full Text] [Related]
15. MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology.
Mateos MV; Landgren O
Cancer Treat Res; 2016; 169():3-12. PubMed ID: 27696254
[TBL] [Abstract][Full Text] [Related]
16. Smoldering multiple myeloma: the role of different scoring systems in identifying high-risk patients in real-life practice.
Cocito F; Mangiacavalli S; Ferretti VV; Cartia CS; Ganzetti M; Benveuti P; Pompa A; Catalano M; Fugazza E; Landini B; Arcaini L; Corso A
Leuk Lymphoma; 2019 Dec; 60(12):2968-2974. PubMed ID: 31169049
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Advances in the Management of Smoldering Myeloma.
Khan R; Zahid U; Kollu V; Jahan N; Ali M; Tricot G; Anwer F
Am J Ther; 2020; 27(2):e194-e203. PubMed ID: 31842112
[TBL] [Abstract][Full Text] [Related]
18. Smoldering Multiple Myeloma: Emerging Concepts and Therapeutics.
Sundararajan S; Kumar A; Korde N; Agarwal A
Curr Hematol Malig Rep; 2016 Apr; 11(2):102-10. PubMed ID: 26894382
[TBL] [Abstract][Full Text] [Related]
19. Immunoparesis defined by heavy/light chain pair suppression in smoldering multiple myeloma shows initial isotype specificity and involves other isotypes in advanced disease.
Isola I; Moreno DF; Moga E; Mena MP; Tovar N; Rodríguez-Lobato LG; Oliver-Caldés A; Salgado MC; Brasó-Maristany F; Yagüe J; Cibeira MT; Prat A; Rosiñol L; Bladé J; Fernández de Larrea C
Ann Hematol; 2021 Dec; 100(12):2997-3005. PubMed ID: 34463804
[TBL] [Abstract][Full Text] [Related]
20. Mode of progression in smoldering multiple myeloma: a study of 406 patients.
Abdallah NH; Lakshman A; Kumar SK; Cook J; Binder M; Kapoor P; Dispenzieri A; Gertz MA; Lacy MQ; Hayman SR; Buadi FK; Dingli D; Lin Y; Kourelis T; Warsame R; Bergsagel L; Rajkumar SV
Blood Cancer J; 2024 Jan; 14(1):9. PubMed ID: 38228628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
